Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen

被引:194
|
作者
Sekyere, John Osei [1 ]
机构
[1] Kwame Nkrumah Univ Sci & Technol, Dept Pharmaceut, Fac Pharm & Pharmaceut Sci, Kumasi, Ghana
来源
MICROBIOLOGYOPEN | 2018年 / 7卷 / 04期
关键词
antifungal resistance; Candida auris; candidaemia; fungemia; molecular epidemiology; DESORPTION IONIZATION-TIME; FLIGHT MASS-SPECTROMETRY; HEALTH-CARE FACILITIES; HAEMULONII COMPLEX; ANTIFUNGAL SUSCEPTIBILITY; RAPID IDENTIFICATION; NOSOCOMIAL FUNGEMIA; BROTH MICRODILUTION; AMPHOTERICIN-B; UNITED-STATES;
D O I
10.1002/mbo3.578
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
From 2009, Candida auris has emerged as a multidrug-resistant ascomycete yeast pathogen with the capacity for easy transmission between patients and hospitals, as well as persistence on environmental surfaces. Its association with high mortalities, breakthrough and persistent candidaemia, inconsistencies in susceptibility testing results, misidentification by available commercial identification systems and treatment failure, complicates its management and detection. Within the last nine years, C. auris has been increasingly reported from far-Eastern Asia, the Middle East, Africa, Europe, South and North America with substantial fatalities and misidentification. Herein, I provide a systematic and thorough review of this emerging pathogen. Meta-analysis showed that at least 742 C. auris isolates have been reported in 16 countries, with most of these being from India (>= 243), USA (>= 232) and UK (>= 103) (p-value=.0355) within 2013-2017. Most isolates were from males (64.76%) (p-value=.0329) and blood (67.48%) (p-value<.0001), with substantial crude mortality (29.75%) (p-value=.0488). Affected patients presented with other comorbidities: diabetes (>= 52), sepsis (>= 48), lung diseases (>= 39), kidney diseases (>= 32) etc. (p-value<.0001). Resistance to fluconazole (44.29%), amphotericin B (15.46%), voriconazole (12.67%), caspofungin (3.48%) etc. were common (p-value=.0059). Commonly used diagnostic tools included PCR (30.38%), Bruker MALDI-TOF MS (14.00%), Vitek 2 YST ID (11.93%), AFLP (11.55%) and WGS (10.04%) (p-value=.002). Multidrug resistance, high attributable mortality and persistence are associated with C. auris infections. Two novel drugs, SCY-078 and VT-1598, are currently in the pipeline. Contact precautions, strict infection control, periodic surveillance and cleaning with chlorine-based detergents, efficient, faster and cheaper detection tools are necessary for prevention, containment and early diagnosis of C. auris infections.
引用
收藏
页数:29
相关论文
共 50 条
  • [1] Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen (vol 7. e578, 2018)
    Sekyere, John Osei
    MICROBIOLOGYOPEN, 2019, 8 (08):
  • [2] Candida auris: An emerging multidrug-resistant pathogen
    Sears, David
    Schwartz, Brian S.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2017, 63 : 95 - 98
  • [3] Comprehensive Overview of Candida auris: An Emerging Multidrug-Resistant Fungal Pathogen
    Kim, Ji-Seok
    Cha, Hyunjin
    Bahn, Yong-Sun
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2024, 34 (07) : 1365 - 1375
  • [4] Current global status of Candida auris an emerging multidrug-resistant fungal pathogen: bibliometric analysis and network visualization
    Ettadili, Hamza
    Vural, Caner
    BRAZILIAN JOURNAL OF MICROBIOLOGY, 2024, 55 (01) : 391 - 402
  • [5] Current global status of Candida auris an emerging multidrug-resistant fungal pathogen: bibliometric analysis and network visualization
    Hamza Ettadili
    Caner Vural
    Brazilian Journal of Microbiology, 2024, 55 : 391 - 402
  • [6] Multi-omits Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen
    Zamith-Miranda, Daniel
    Heyman, Heino M.
    Cleare, Levi G.
    Couvillion, Sneha P.
    Clair, Geremy C.
    Bredeweg, Erin L.
    Gacser, Attila
    Nimrichter, Leonardo
    Nakayasu, Ernesto S.
    Nosanchuk, Joshua D.
    MSYSTEMS, 2019, 4 (04)
  • [7] Candida auris: the most talked about multidrug-resistant emerging fungal pathogen
    Irinyi, Laszlo
    Malik, Richard
    Meyer, Wieland
    MICROBIOLOGY AUSTRALIA, 2022, 43 (04) : 173 - 176
  • [8] Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida auris
    Kordalewska, Milena
    Zhao, Yanan
    Lockhart, Shawn R.
    Chowdhary, Anuradha
    Berrio, Indira
    Perlin, David S.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2017, 55 (08) : 2445 - 2452
  • [9] Management of an Emerging Multidrug-Resistant Fungus: Candida auris
    Ng, Kimberly E.
    Lee, Yuman
    US PHARMACIST, 2020, 45 (04) : HS1 - HS6
  • [10] Multidrug-resistant Candida auris: an epidemiological review
    Chakrabarti, Arunaloke
    Singh, Shreya
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (06) : 551 - 562